20405 ⎘
Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom; Quinolines; Isoquinolines Morphinan derivatives, e.g. morphine, codeine
Treatment and management of augmentation in restless legs syndrome
#1502PHARMACEUTICAL COMPOSITIONS
#1503Transoral dosage forms comprising sufentanil
#1504COMPOSITIONS COMPRISING S1P RECEPTOR MODULATORS
#1505Medications For Deposition On Biological Surfaces
#1506DOSAGE FORM FOR ADMINISTRATION OF OPIOID ANTAGONISTS
#1507ARTICLE FOR STORAGE OF THIN-FILM DRUG
#1508TRANSDERMAL DELIVERY SYSTEM
#1509TRANSDERMAL DELIVERY SYSTEM
#1510Anti-CGRP compositions and use thereof
#1511Anti-CGRP compositions and use thereof
#1512Anti-CGRP compositions and use thereof
#1513Anti-CGRP compositions and use thereof
#1514Pharmaceutical preparation containing oxycodone and naloxone
#1515METHODS FOR ATTENUATING OR PREVENTING MU(μ)-OPIOID RECEPTOR MEDIATED TOLERANCE AND OPIOID-INDUCED HYPERALGESIA
#1516Compounds for Treatment or Prevention of Disorders of the Nervous System and Symptoms and Manifestations Thereof, and for Cyto-Protection Against Diseases and Aging of Cells, and Symptoms and Manifestations Thereof
#1517DIAGNOSTIC TOOLS FOR CHARCOT-MARIE-TOOTH DISEASE
#1518TREATMENT OF CANCER WITH NALTREXONE
#1519Bupropion as a modulator of drug activity
#1520AUTOMATIC OPIOID ANTAGONIST INJECTION SYSTEM
#1521Crystalline forms of an 8-azabicyclo[3.2.1]octane compound
#1522MULTIPLE PILL ABUSE-RESISTANT IMMEDIATE RELEASE SOLID DOSAGE FORM OF HYDROCODONE
#1523Liposome loading
#1524TRANSMUCOSAL DRUG DELIVERY DEVICES FOR USE IN CHRONIC PAIN RELIEF
#1525TRANSDERMAL DELIVERY SYSTEM
#1526LOW-TEMPERATURE STABLE OPIOID ANTAGONIST SOLUTIONS
#1527Systems and methods for treating an opioid-induced adverse pharmacodynamic response
#1528Oral pharamaceutical dosage forms
#1529PHARMACEUTICAL COMPOSITION COMPRISING AMLODIPINE AND DEXTROMETHORPHAN
#1530Pharmaceutical compositions and methods
#1531Method of treating dyskinesia
#1532Immediate release abuse-deterrent granulated dosage forms
#1533ABUSE-RESISTANT CONTROLLED-RELEASE OPIOID DOSAGE FORM
#1534ABUSE DETERRENT PHARMACEUTICAL COMPOSITIONS
#1535MISUSE PREVENTATIVE, CONTROLLED RELEASE FORMULATION
#1536MISUSE PREVENTATIVE, CONTROLLED RELEASE FORMULATION
#1537Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
#1538Compositions for the Restoration of a Fecal Microbiota and Methods for Making and Using Them
#1539FORMULATIONS FOR MITIGATING OPIOID OVERDOSE AND METHODS OF MAKING AND USING THE SAME
#1540Oxidation-stabilized tamper-resistant dosage form
#1541Pharmaceutical compositions
#1542IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE
#1543Compositions for drug administration
#1544ABUSE-RESISTANT CONTROLLED-RELEASE OPIOID DOSAGE FORM
#1545CO-PACKAGED DRUG PRODUCTS
#1546Acetate salt of buprenorphine and methods for preparing buprenorphine
#1547Vaporized medicants and methods of use
#1548INTRANASAL NALOXONE COMPOSITIONS AND METHODS OF MAKING AND USING SAME
#1549Injectable flowable composition comprising buprenorphine
#1550Abuse-proof solid pharmaceutical composition
#1551Methods of treating pancreatic cancer using GPCR antagonists
#1552Method of increasing satellite cell proliferation with an HDAC inhibitor
#1553Solid Dispersion Comprising μ-Opioid Antagonists
#1554Tamper resistant dosage forms
#1555Tamper resistant dosage forms
#1556ALCOHOL RESISTANT DOSAGE FORMS
#1557LIQUID BUPRENORPHINE FORMULATIONS
#1558Liquid compositions for treating cough or cold symptoms
#1559COMBINATIONS OF OPIOID/TLR4 ANTAGONISTS AND ACETAMINOPHEN FOR USE IN THE TREATMENT OF EMOTIONAL PAIN AND INSOMNIA
#1560Devices and methods for facilitating and controlling use of a medication
#1561Pharmaceutical Formulation Containing Gelling Agent
#1562ABUSE-PROOFED ORAL DOSAGE FORM
#1563Liquid naloxone spray
#1564METHOD FOR ISOLATION OF ALKALOIDS AND AMINO ACIDS, AND COMPOSITIONS CONTAINING ISOLATED ALKALOIDS AND AMINO ACIDS
#1565Acylated glucagon analogues
#1566Breathing control modulating compounds, and methods of making and using same
#1567Method for treating a GD2 positive cancer
#1568TRANSMUCOSAL DELIVERY DEVICES WITH ENHANCED UPTAKE
#1569COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN
#1570TREATMENT OF PRURIGO NODULARIS
#1571Pharmaceutical Formulation Containing Gelling Agent
#1572Injectable flowable composition comprising buprenorphine
#1573Abuse Deterrent Pharmaceutical Composition
#1574MAPC treatment of brain injuries and diseases
#1575COMBINATIONS OF OPIOIDS AND N-ACYLETHANOLAMINES
#1576BUPROPION AND DEXTROMETHORPHAN FOR TREATING NICOTINE ADDICTION
#1577Stimulant abuse-deterrent compositions
#1578METHOD, SYSTEM AND APPARATUS FOR CONTROLLED DELIVERY OF OPIOID AND OTHER MEDICATIONS
#1579SYSTEM AND METHODS FOR OVERDOSE MITIGATION
#1580Enteric combination therapy
#1581Polymorphic forms of naltrexone
#1582CHEWING GUM COMPOSITION COMPRISING CANNABINOIDS AND OPIOID AGONISTS AND/OR ANTAGONISTS
#1583COMPOSITIONS, METHODS AND KITS FOR THE SAFE INHALED DELIVERY OF TARGETED OPIOIDS FOR THE TREATMENT OF PAIN AND ADDICTION
#1584Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
#1585Systems and methods for treating an opioid-induced adverse pharmacodynamic response
#1586METHODS OF TREATMENT COMPRISING ADMINISTERING A HIGH DAILY DOSE OF OXYCODONE AND NALOXONE IN A 2:1 WEIGHT RATIO
#1587NEW ABUSE-RESISTANT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCE
#1588ABUSE DETERRENT PHARMACEUTICAL COMPOSITIONS
#1589ORAL FILM PREPARATION
#1590ABUSE RESISTANT TRANSMUCOSAL DRUG DELIVERY DEVICE
#1591Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment
#1592PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
#1593Particles containing an opioid receptor antagonist and methods of use
#1594Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
#1595TRANSDERMAL DELIVERY SYSTEM
#1596MEDICATED SPRAY FOR TREATMENT OF SUBSTANCE ABUSE, OVERDOSE, ADDICTION AND IMPULSE CONTROL DISORDERS
#1597Antihistamine compositions, combinations, and use thereof
#1598Opioid compositions resistant to overdose and abuse
#1599Extended relief dosage form
#1600TAMPER-RESISTANT DOSAGE FORM WITH IMMEDIATE RELEASE AND RESISTANCE AGAINST SOLVENT EXTRACTION
#1601Compositions of buprenorphine and μ antagonists
#1602Compositions of buprenorphine and μ antagonists
#1603ANTI-OVERINGESTION DOSAGE FORMS
#1604ORAL DOSAGE FORMS FOR OXYGEN-CONTAINING ACTIVE AGENTS AND OXYL-CONTAINING POLYMER
#1605Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
#1606Naltrexone Long Acting Formulations and Methods of Use
#1607ABUSE-RESISTANT MUCOADHESIVE DEVICES FOR DELIVERY OF BUPRENORPHINE
#1608Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
#1609IMMEDIATE RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING OXYCODONE AND NALOXONE
#1610STABLE INFUSION DOSAGE FORM OF MORPHINE
#1611Anise flavored medication
#1612Orally administrable formulation
#1613Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same
#1614Morphinan derivative
#1615Medication With Improved Taste And Sensory Experience
#1616METHODS AND COMPOSITIONS FOR TREATMENT OF DERMAL AND EPIDERMAL WOUNDS
#1617Abuse deterrent dosage forms
#1618Process for the preparation of benzhydrocodone hydrochloride
#1619Method for Treating And Preventing Protozoal Infections
#1620Immediate release oral guaifenesin solution
#1621Pharmaceutical formulation containing gelling agent
#1622Combination dosage form of a mu opioid receptor antagonist and an opioid agent
#1623Liquisoft capsules
#1624ABUSE-RESISTANT FORMULATIONS
#1625NEW ABUSE-RESISTANT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCE
#1626Use of amisulpride as an anti-emetic
#1627Tamper resistant oral opioid agonist formulations
#1628Sustained release formulation of nalbuphine
#1629Orvinol and thevinol derivatives useful in the treatment of drug and alcohol abuse, depression, anxiety, or a compulsive disorder
#1630Methods and compositions for wound healing
#1631TAMPER RESISTANT DOSAGE FORM COMPRISING AN ANIONIC POLYSACCHARIDE
#1632PERIPHERAL KAPPA OPIOID RECEPTOR AGONISTS FOR HARD TISSUE PAIN
#1633Abuse-deterrent pharmaceutical compositions of opioids and other drugs
#1634ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS
#1635ABUSE DETERRENT COMPOSITIONS AND METHODS OF MAKING SAME
#1636Nalmefene for reduction of alcohol consumption in specific target populations
#1637Transdermal therapeutic system with an overtape comprising two adhesive layers
#1638Encased Tamper Resistant Controlled Release Dosage Forms
#1639Process for preparing oxycodone compositions
#1640PHARMACEUTICAL FORMULATION CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST AND GELLING AGENT
#1641SIGMA LIGANDS FOR POTENTIATING THE ANALGESIC EFFECT OF OPIOIDS AND OPIATES IN POST-OPERATIVE PAIN AND ATTENUATING THE DEPENDENCY THEREOF
#1642Pharmaceutical formulation containing gelling agent
#1643Morphan and morphinan analogues, and methods of use
#1644Vaginal Drug Delivery Device
#1645PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY
#1646Vaporized medicants and methods of use
#1647INJECTABLE BUPRENORPHINE FORMULATION
#1648Therapy for vitiligo
#1649PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF DEPRESSION, ANXIETY, AND NEURODEGENERATIVE DISORDERS
#1650Processes For Preparing Morphinan-6-One Products With Low Levels Of Alpha, Beta-Unsaturated Ketone Compounds
#1651BUPRENORPHINE WAFER FOR DRUG SUBSTITUTION THERAPY
#1652USE OF OPIOID ANTAGONISTS
#1653DOSAGE FORM CONTAINING OXYCODONE AND NALOXONE
#1654TREATMENT OF UREMIC PRURITUS
#1655Oral dosage form containing a fast release exterior coating
#1656IMMEDIATE RELEASE, ABUSE DETERRENT PHARMACEUTICAL COMPOSITIONS
#1657MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES
#1658COMPOSITIONS FOR DRUG ADMINISTRATION
#1659COMPOSITIONS AND METHODS FOR THE TREATMENT OF ZELLWEGER SPECTRUM DISORDER
#1660Early treatment of CMT disease
#1661Intravenous administration of tramadol
#1662Modified Alginate Hydrogels for Therapeutic Agents, their Preparation and Methods Thereof
#1663SUBLINGUAL AND BUCCAL FILM COMPOSITIONS
#1664Combined herbal and pharmaceutical composition and method
#1665Polysubunit opioid prodrugs resistant to overdose and abuse
#1666Process of making stable abuse-deterrent oral formulations
#1667CRYSTAL FORMS OF APOMORPHINE AND USES THEREOF
#1668Formulations and Methods for Attenuating Respiratory Depression Induced by Opioid Overdose
#1669Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
#1670GLUTAMATE AGENTS IN THE TREATMENT OF MENTAL DISORDERS
#1671Bupropion as a modulator of drug activity
#1672Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
#1673PHARMACEUTICAL COMPOSITIONS
#1674TREATING POSTOPERATIVE NAUSEA AND VOMITING
#1675Abuse-deterrent drug formulations
#1676PATCH DEVICES, METHODS AND APPARATUS FOR FORMING, AND TESTING PHARMACEUTICAL AGENT DELIVERY PATCH DEVICES
#1677METHODS AND COMPOSITIONS FOR TREATING MIGRAINES USING NORIBOGAINE
#1678Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant agent
#1679Buprenorphine dosing regimens
#1680ENHANCEMENT OF IMPAIRED MOTOR AND MENTAL FUNCTIONS, USING DEXTROMETHORPHAN AND OXIDASE ENZYME INHIBITOR
#1681Bupropion as a modulator of drug activity
#1682TAMPER RESISTANT DOSAGE FORMS
#1683PHARMACEUTICAL COMPOSITIONS
#16848-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
#1685PHARMACEUTICAL COMPOSITIONS
#1686PHARMACEUTICAL COMPOSITIONS
#1687Pharmaceutical compositions
#1688Porous particles
#1689ENHANCEMENT OF IMPAIRED MOTOR AND MENTAL FUNCTIONS, USING DEXTROMETHORPHAN AND OXIDASE ENZYME INHIBITOR
#1690TAMPER RESISTANT DOSAGE FORMS
#1691TAMPER RESISTANT DOSAGE FORMS
#1692SOLID ORAL PHARMACEUTICAL COMPOSITION
#1693TAMPER RESISTANT DOSAGE FORMS
#1694Medical implant
#1695Chemically stable compositions of a pharmaceutical active agent in a multi- chambered delivery system for mucosal delivery
#1696PHARMACEUTICAL COMPOSITIONS
#1697Oxycodone formulations
#1698Sublingual opioid formulations containing naloxone
#1699Immediate Release Abuse Deterrent Liquid Fill Dosage Form
#1700Opioid receptor modulators
#1701PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF AGITATION IN DEMENTIA
#1702Morphinan Derivatives for the Treatment of Drug Overdose
#1703Methods of treating hyperalgesia
#1704ABUSE DETERRENT PHARMACEUTICAL COMPOSITIONS FOR CONTROLLED RELEASE
#1705Process for the formation of hydrocodone bitatrate
#1706METAP2 inhibitors and methods of treating obesity
#1707Abrasion-Resistant Opioid Formulations
#1708COMBINATIONS OF OPIOID/TLR4 ANTAGONIST AND ACETYL-PARA-AMINOPHENOL (APAP) FOR USE IN THE REDUCTION OF TOLL-LIKE RECEPTOR 4(TLR4) AND CYCLOOXYGENASE-2 (COX-2) ACTIVITY
#1709Abuse resistant pharmaceutical compositions
#1710Tamper-resistant pharmaceutical compositions of opioids and other drugs
#1711Method of manufacturing buprenorphine and analogues thereof from oripavine
#1712Oral Pharmaceutical Dosage Forms
#1713TAMPER RESISTANT DOSAGE FORMS
#1714TAMPER RESISTANT DOSAGE FORMS
#1715TAMPER RESISTANT DOSAGE FORMS
#1716TAMPER RESISTANT DOSAGE FORMS
#1717TAMPER RESISTANT DOSAGE FORMS
#1718TAMPER RESISTANT DOSAGE FORMS
#1719TAMPER RESISTANT DOSAGE FORMS
#1720TAMPER RESISTANT DOSAGE FORMS
#1721TAMPER RESISTANT DOSAGE FORMS
#1722TAMPER RESISTANT DOSAGE FORMS
#1723TAMPER RESISTANT DOSAGE FORMS
#1724ENHANCED STABILITY OF NOVEL LIQUID COMPOSITIONS
#1725Method for administering omega-conopeptide
#1726CRUSH RESISTANT DELAYED-RELEASE DOSAGE FORMS
#1727Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof
#1728COMPOSITIONS AND METHODS FOR REDUCING FOOD CRAVINGS
#1729PHARMACEUTICAL DOSAGE FORMS
#1730TRANSMUCOSAL DELIVERY DEVICES WITH ENHANCED UPTAKE
#1731Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
#1732IMMEDIATE RELEASE ABUSE DETERRENT TABLET
#1733NOVEL PHARMACEUTICAL FORMULATION
#1734NASAL DRUG PRODUCTS AND METHODS OF THEIR USE
#1735Use of nalmefene in non-alcoholic steatohepatitis
#1736Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
#1737Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
#1738PHARMACEUTICAL CAPSULE CONTAINING AT LEAST TWO TABLETS
#1739INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE
#1740Methods of treating disease using auricular peripheral nerve field stimulation
#1741Tamper resistant pharmaceutical formulations
#1742Pharmaceutical Formulation Containing Gelling Agent
#1743COMPOSITIONS FOR CONTROL OF DRUG ABUSE
#1744SUBLINGUAL AND BUCCAL FILM COMPOSITIONS
#1745MODIFIED RELEASE ABUSE DETERRENT DOSAGE FORMS
#1746Tamper resistant dosage form with bimodal release profile
#1747Benzomorphan analogs and the use thereof
#1748Aerosol forming device for use in inhalation therapy
#1749Injectable flowable composition comprising buprenorphine
#1750Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
#1751Morphinan compounds
#1752Extended release, abuse deterrent dosage forms
#1753Pharmaceutical compositions
#1754DEGRADABLE NETWORKS FOR SUSTAINED RELEASE AND CONTROLLED RELEASE DEPOT DRUG DELIVERY APPLICATIONS
#1755ADMINISTRATION OF INTRAVENOUS IBUPROFEN
#1756Systems and Methods for Compounding Injectable Therapeutic Agents
#1757Modified release formulations containing drug-ion exchange resin complexes
#1758Pharmaceutical composition having abuse deterrent properties
#1759PATCH PREPARATIONS WITH MISUSE PREVENTION FEATURES
#1760Novel Alpha-Hydroxy Carboxylic Acid and Derivatives and Other GRAS-Based Prodrugs of Oxymorphone and Uses Thereof
#1761Particulate materials
#1762Opioid peptide
#1763Dihydroetorphines and their preparation
#1764Compositions for the Restoration of a Fecal Microbiota and Methods for Making and Using Them
#1765NON ADDICTIVE MORPHINE PLUS BUSPIRONE COMBINATION FOR THE TREATMENT OF PAIN
#1766Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive
#1767Compositions and methods for reducing overdose
#1768Stable pharmaceutical formulations of methylnaltrexone
#1769USE OF OPIOID ANTAGONISTS TO ATTENUATE ENDOTHELIAL CELL PROLIFERATION AND MIGRATION
#1770ENCAPSULATING LIPOSOMES
#1771USE OF MESO- AND NANOPOROUS MATERIAL FOR SURFACTANT TRAPPING IN NANOPARTICLE SUSPENSIONS
#1772Liquid naloxone spray
#1773USE OF OPIOID ANTAGONISTS TO ATTENUATE ENDOTHELIAL CELL PROLIFERATION AND MIGRATION
#1774Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
#1775Orally administrable composition
#1776Acetaminophen-Containing Analgesic Formulations With Reduced Hepatotoxicity
#1777ABUSE RESISTANT TRANSMUCOSAL DRUG DELIVERY DEVICE
#1778ABUSE-RESISTANT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCE
#1779Nasal drug products and methods of their use
#1780Sustained Release Buprenorphine Microshperes (SRBM) and Methods of Use Thereof
#1781Method for Inducing a Sustained Immune Response
#1782Method for inducing a sustained immune response
#1783Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders
#1784ABUSE-PROOFED DOSAGE FORM
#1785Process for making controlled release medical implant and non-implant products
#1786Devices and methods for delivering opioid antagonists including formulations for naloxone
#1787Opioid peptide
#1788Methods and Compositions for Treating Vasomotor Symptoms
#1789MATRIX FOR SUSTAINED, INVARIANT AND INDEPENDENT RELEASE OF ACTIVE COMPOUNDS
#1790MULTIDIRECTIONAL MUCOSAL DELIVERY DEVICES AND METHODS OF USE
#1791Intranasal Pharmaceutical Dosage Forms Comprising Naloxone
#1792SOLID SALT FORM OF ALPHA-6-MPEG6-O-HYDROXYCODONE AS OPIOID AGONISTS AND USES THEREOF
#1793Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof
#1794Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, AIDs, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
#1795STABLE PRESERVATIVE FREE OPHTHALMIC FORMULATIONS OF OPIOID ANTAGONISTS
#1796Glucomannan containing pharmaceutical compositions with extended release and abuse deterrent properties
#1797TRANSDERMAL THERAPEUTIC SYSTEM FOR ADMINISTERING THE ACTIVE SUBSTANCE BUPRENORPHINE
#1798Patch
#1799Methods of treating overweight and obesity
#1800Methods for treating depressive symptoms